De Smedt Fabian, Dessy Frédérique, Carestia Luciano, Baldin Pamela, Nana Frank Aboubakar, Clapuyt Philippe, Boon Véronique, Amant Frédéric, Mhallem Gziri Mina
Department of Obstetrics, Clinique Saint-Pierre, 1340 Ottignies, Belgium.
Department of Obstetrics, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
Oncol Lett. 2022 Dec 20;25(2):54. doi: 10.3892/ol.2022.13640. eCollection 2023 Feb.
Oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene account for 5% of non-small cell lung cancer (NSCLC) cases. ALK inhibitors have markedly improved the outcome of metastatic ALK-positive NSCLC (ALK mNSCLC) by increasing long-term overall survival. Although a diagnosis of NSCLC during pregnancy or the peripartum period is rare, ALK NSCLC accounts for 38% of NSCLC cases in women of childbearing age (18-45 years old). The younger age and prolonged survival of patients with ALK mNSCLC bring new challenges for lung cancer and obstetrics research, and raises questions related to pregnancy and family planning. The present study described normal fetal development and no obstetric complications in a patient infected with HIV diagnosed with ALK mNSCLC, who became pregnant during treatment with alectinib, a third-generation ALK inhibitor.
间变性淋巴瘤激酶（ALK）基因的致癌重排在非小细胞肺癌（NSCLC）病例中占5%。ALK抑制剂通过提高长期总生存率，显著改善了转移性ALK阳性NSCLC（ALK mNSCLC）的治疗效果。虽然孕期或围产期诊断为NSCLC的情况很少见，但ALK NSCLC在育龄女性（18 - 45岁）的NSCLC病例中占38%。ALK mNSCLC患者较年轻且生存期延长，给肺癌和产科研究带来了新挑战，并引发了与妊娠和计划生育相关的问题。本研究描述了一名感染HIV且被诊断为ALK mNSCLC的患者在接受第三代ALK抑制剂阿来替尼治疗期间怀孕，其胎儿正常发育且无产科并发症。
